中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 12
Dec.  2013
Turn off MathJax
Article Contents

Effect of pegylated interferon α-2a combined with thymosin α1 on quality of life in patients with chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2013.12.012
  • Received Date: 2013-03-25
  • Published Date: 2013-12-20
  • Objective To investigate the effect of pegylated interferonα-2a ( PEG-IFN α-2a) combined with thymosin α1 ( Tα1) on the quality of life ( QOL) in patients with chronic hepatitis B ( CHB) . Methods A total of 148 patients with CHB who were admitted to our department from October 2008 to October 2012 were selected and randomly divided into observation group ( n = 74) and control group ( n =74) . The control group was treated with PEG-IFN α-2a, while the observation group was treated with PEG-IFN α-2a plus Tα1. The hepatitis B virus ( HBV) DNA load, QOL, Chronic Liver Disease Questionnaire scores, and adverse reactions were compared between the two groups at months 3, 6, and 12 of treatment. Comparisons between groups were made by independent-samples t test; comparisons between variables before and after treatment were made by paired t test; categorical data were analyzed by chi-square test. Results Compared with the control group, the observation group had significantly higher decrease in HBV DNA load and virological response rate at months 3 ( t = 2. 281, P = 0. 02; χ2= 3. 950, P = 0. 04) , 6 ( t = 3. 237, P = 0. 00; χ2= 4. 022, P = 0. 04) , and 12 ( t = 3. 197, P = 0. 00;χ2= 4. 028, P = 0. 04) , significantly higher overall QOL, physiological, social relation, fatigue, and anxiety scores at month 6 ( t = 2. 039-3. 472, P < 0. 05) , and significantly higher overall QOL, general health status, physiological, psychological, social relation, fatigue, systemic symptom, activity, anxiety, and environment scores at month 12 ( t = 2. 020-3. 201, P < 0. 05) . Conclusion PEG-IFN α-2a combined with Tα1 can improve immunity and antiviral ability and promote HBV clearance in the treatment of CHB, thus leading to the improvement in patients' QOL. This therapy holds promise for clinical application.

     

  • loading
  • [1]DING N.A randomized controlled study ofα-1-thymosin combined with peginterferonα-2a in the treatment of chronic hepatit B[J].China Modern Doctor, 2011, 49 (26) :144-145. (in Chinese) 丁宁.聚乙二醇干扰素α-2a联合胸腺肽α1治疗慢性乙型肝炎随机对照观察[J].中国现代医生, 2011, 49 (26) :144-145.
    [2] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B (2010 version) [J].J Clin Hepatol, 2011, 27 (1) :I-XVI. (in Chinese) 中华医学会肝病学分会, 感染病学分会.慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, 27 (1) :I-XVI.
    [3]CASANOVAS T, JANL, HERDMAN M, et al.Assessing outcomes in liver disease patients:reliability and validity of the Spanish version of the Liver Disease Quality of Life Questionnaire (LDQOL 1.0) [J].Value Health, 2010, 13 (4) :455-462.
    [4]YOUNOSSI ZM, GUYATT G, KIWI M, et al.Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease[J].Gut, 1999, 45 (2) :295-300.
    [5]PAN L, WEI X, XIE YM, et al.Anti-viral therapy with pegylated interferon alpha-2a plus ribavirin in patients coinfected with HBV and HCV[J].J Clin Hepatol, 2011, 27 (1) :84-85. (in Chinese) 潘蕾, 魏欣, 谢玉梅, 等.聚乙二醇干扰素α-2a治疗慢性丙型肝炎病毒/乙型肝炎病毒共感染临床疗效[J].临床肝胆病杂志, 2011, 27 (1) :84-85.
    [6]LI XH, LAI JQ, LI YX, et al.Therapeutic efficacy of the combination of entecavir and thymosin alpha 1 on patients with HBeAgpositive chronic hepatitis B[J].Infect Dis Info, 2012, 25 (4) :234-236. (in Chinese) 李旭红, 赖江琼, 李奕鑫, 等.恩替卡韦片联合胸腺肽α1治疗HBeAg阳性乙型肝炎疗效分析[J].传染病信息, 2012, 25 (4) :234-236.
    [7]CUI JJ, JIANG XL, ZHOU BP, et al.Thymosin-αl improving efficacy of peginterferon alfa-2a treatment in patients with HbeAgpositive chronic hepatitis B[J].Chin Hosp Pharm J, 2008, 28 (10) :823-825. (in Chinese) 崔建军, 蒋小玲, 周伯平, 等.聚乙二醇干扰素α-2a联合胸腺肽α1治疗HBeAg阳性慢性乙型肝炎[J].中国医院药学杂志, 2008, 28 (10) :823-825.
    [8]ZHANG Y, LI G, CHEN L, et al.Clinical effect of pegylated interferonα-2a combined with thymosinα1 in treatment of chronic hepatitis B[J].China Modern Doctor, 2009, 47 (27) :78-79. (in Chinese) 张颖, 李刚, 陈琳, 等.聚乙二醇干扰素α-2a与胸腺肽α1联合治疗慢性乙型肝炎的临床研究[J].中国现代医生, 2009, 47 (27) :78-79.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (3009) PDF downloads(519) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return